Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
DRUG
Upturn stock ratingUpturn stock rating

Bright Minds Biosciences Inc (DRUG)

Upturn stock ratingUpturn stock rating
$42.54
Last Close (24-hour delay)
Profit since last BUY25.63%
upturn advisory
Strong Buy
BUY since 14 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: DRUG (3-star) is a STRONG-BUY. BUY since 14 days. Profits (25.63%). Updated daily EoD!

Upturn Star Rating

rating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

6 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $94.01

1 Year Target Price $94.01

Analysts Price Target For last 52 week
$94.01 Target price
52w Low $0.94
Current$42.54
52w High $79.02

Analysis of Past Performance

Type Stock
Historic Profit 2231.48%
Avg. Invested days 37
Today’s Advisory Strong Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 308.95M USD
Price to earnings Ratio -
1Y Target Price 94.01
Price to earnings Ratio -
1Y Target Price 94.01
Volume (30-day avg) 6
Beta 0.17
52 Weeks Range 0.94 - 79.02
Updated Date 08/15/2025
52 Weeks Range 0.94 - 79.02
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.4

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -10.57%
Return on Equity (TTM) -11.21%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 268250896
Price to Sales(TTM) -
Enterprise Value 268250896
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.07
Shares Outstanding 7083240
Shares Floating 2983319
Shares Outstanding 7083240
Shares Floating 2983319
Percent Insiders 22.42
Percent Institutions 78.63

ai summary icon Upturn AI SWOT

Bright Minds Biosciences Inc

stock logo

Company Overview

overview logo History and Background

Bright Minds Biosciences Inc. was founded in 2019 and is focused on developing novel therapeutics for neuropsychiatric disorders, epilepsy, and pain. The company is developing a portfolio of next-generation serotonin 5-HT2C receptor agonists.

business area logo Core Business Areas

  • Drug Development: Bright Minds focuses on developing and commercializing novel small molecule therapeutics for neurological and psychiatric disorders with unmet medical needs, with a focus on 5-HT2C receptor agonists.
  • Research and Development: The company's R&D efforts are centered on preclinical and clinical studies of its drug candidates.

leadership logo Leadership and Structure

Ian McDonald serves as the CEO. The company has a scientific advisory board comprising experts in neuroscience and drug development.

Top Products and Market Share

overview logo Key Offerings

  • BMB-101: BMB-101, Bright Minds' lead product candidate, is a selective 5-HT2C receptor agonist being developed for Dravet Syndrome and other treatment-resistant epilepsies. Currently in preclinical development. Market share data is not yet available, it is under development. Competitors include other anti-epileptic medications such as Epidiolex (GWPH) and various other therapies from companies such as Zogenix (acquired by UCB).
  • BMB-202: BMB-202, Bright Mindsu2019 investigational compound, designed to activate the 5-HT2C receptor. It is under development to potentially address the high unmet medical need in patients suffering from neuropsychiatric disorders and is currently in preclinical development. Market share data is not yet available, it is under development. Competitors include established antipsychotics and antidepressants from companies like Eli Lilly (LLY) and Pfizer (PFE).

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is competitive, with ongoing research into new treatments for neurological and psychiatric disorders. Advances in neuroscience are driving the development of more targeted therapies.

Positioning

Bright Minds is positioned as a company developing next-generation therapies focusing on 5-HT2C receptor modulation. Their competitive advantage lies in their selective agonist approach.

Total Addressable Market (TAM)

The TAM for neuropsychiatric disorders and epilepsy treatments is estimated to be in the billions of dollars. Bright Minds targets specific patient populations with unmet needs, which makes TAM more targeted.

Upturn SWOT Analysis

Strengths

  • Novel therapeutic approach
  • Experienced management team
  • Focus on unmet medical needs
  • Strong patent portfolio (pending)

Weaknesses

  • Limited financial resources
  • Early-stage clinical development
  • High regulatory risk
  • Dependence on key personnel

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new indications
  • Positive clinical trial results
  • Orphan drug designation

Threats

  • Competition from established therapies
  • Clinical trial failures
  • Regulatory hurdles
  • Generic entry upon patent expiry

Competitors and Market Share

competitor logo Key Competitors

  • GWPH (now UCB)
  • LLY
  • PFE

Competitive Landscape

Bright Minds competes with established pharmaceutical companies that have existing therapies for neurological and psychiatric disorders. Bright Minds' advantage lies in its targeted 5-HT2C agonist approach, but disadvantages include its small size and early stage of development.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by preclinical development and securing funding.

Future Projections: Future growth depends on the successful completion of clinical trials and potential commercialization or licensing agreements. Analyst estimates are limited due to the early-stage nature of the company.

Recent Initiatives: Recent initiatives include advancing BMB-101 and BMB-202 into clinical trials and exploring potential partnerships.

Summary

Bright Minds Biosciences is an early-stage pharmaceutical company focused on developing novel therapies. It has a promising technology with its selective 5-HT2C receptor agonists. However, it faces several challenges, including limited financial resources, clinical trial risks, and competition from established companies. The company's success hinges on positive clinical trial results and strategic partnerships.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Bright Minds Biosciences Inc. Investor Relations
  • Company Press Releases
  • SEC Filings

Disclaimers:

This analysis is for informational purposes only and does not constitute investment advice. Market share data is based on estimates and may not be precise. Financial data is limited due to the company's early-stage development. The AI rating is based on a limited understanding of the company and should not be used as the sole decision-making factor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Bright Minds Biosciences Inc

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2021-03-22
Co-Founder, CEO, President & Director Mr. Ian McDonald
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York.